We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




POC Diagnostic Platform Combines Immunoassay and Molecular Testing

By LabMedica International staff writers
Posted on 14 May 2025

An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design. More...

This platform not only demonstrates true lab-quality sensitivity, even with the most challenging clinical samples, but also maintains low invalid rates and minimal system downtime.

Cubit Diagnostics (Carlsbad, CA, USA) is further advancing the development of its integrated immunoassay and molecular benchtop analyzer, specifically designed for use in doctor’s offices and pharmacies, eliminating the need for multiple platforms and complicated testing workflows. The Cubit platform leverages a proprietary purification method and affordable microfluidic technologies to provide actionable results exactly when and where they are needed. By integrating cutting-edge target extraction technology with a simple, cost-effective design, CubitDx is addressing long-standing challenges in diagnostics. The result is laboratory-grade performance without sacrificing affordability, supporting the increasing trend of digital health and enabling more accessible care. The platform can simultaneously test up to 8 targets per run, offering comprehensive syndromic testing while performing both immunoassays and molecular testing on a single platform.

While initially focused on COVID-19, Flu A, and Flu B, the CubitDx platform is designed to tackle a wide range of critical health issues, including sepsis, sexually transmitted diseases (STDs), HIV, and HPV in the future. Evaluation results show that the CubitDx platform’s COVID-19 assay provides higher sensitivity than standard rapid tests and matches the sensitivity of large, high-throughput clinical laboratory systems. With the ability to deliver lab-quality results in just 15 minutes at the point of care, the platform aims to bring high-performance diagnostics closer to patients, improving both outcomes and accessibility worldwide. Offering affordable, high-sensitivity diagnostics for both resource-rich and cost-sensitive markets, the CubitDx platform has the potential to revolutionize healthcare access globally, from U.S. hospitals to underserved communities across Asia and Africa.

Related Links:
Cubit Diagnostics


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
New
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.